Introduction {#s1}
============

Over the past decade, various potassium (K^+^) channels have been implicated as important players in the regulation of arterial vascular tone and its control by perivascular adipose tissue (PVAT). Opening of vascular smooth muscle cell (VSMC) K^+^ channels causes K^+^ efflux and membrane hyperpolarization, which leads to reduced Ca^2+^ influx though L-type Ca~V~1.2 channels and consequently arterial relaxation (Nelson and Quayle, [@B28]). A variety of endogenous vasodilators, such as hypoxia, acidosis, as well as metabolites and autacoids (e.g., adenosine, prostacyclin) act as potent K^+^ channel openers to produce relaxation (Sobey, [@B38]; Tano and Gollasch, [@B43]). Noteworthy, many of these substances produce relaxation by opening maxi Ca^2+^ activated (BK~Ca~) K^+^ channels in VSMCs (Bentzen et al., [@B2]). Only very few substances have been reported to relax vessels by opening arterial smooth muscle voltage-gated K~V~ channels (Tanaka et al., [@B42]; Park et al., [@B31]). Among them adenosine and atrial natriuretic peptide (ANP) act *via* activation of the KCNQ (K~V~7) subfamily of K~V~ channels (Khanamiri et al., [@B20]; Stott et al., [@B40]).

Recent studies have demonstrated a paracrine role for PVAT to produce relaxation of arterial smooth muscle cells in a number of vascular beds (Lohn et al., [@B24]; Verlohren et al., [@B45]; Gao et al., [@B14]; Zavaritskaya et al., [@B55]). Certain adipokines, such as adiponectin (Weston et al., [@B50]), angiotensin-1 to 7 (Lee R. M. K. W. et al., [@B22]), methyl palmitate (Lee Y.-C. et al., [@B23]), and notably H~2~S (Schleifenbaum et al., [@B36]) were recently proposed as potential perivascular-derived relaxing factors (PVRFs), which could mediate the anti-contractile properties of PVAT. The paracrine effects of PVAT involve the opening of K^+^ channels, however, the identity of the K^+^ channel subtype(s) involved is still a matter of debate (Tano et al., [@B44]).

Voltage-gated K~V~ channels of the KCNQ (K~V~7) family have been proposed to play an important role in PVAT control of arterial tone. This conclusion is based on observations demonstrating that the anti-contractile effects of PVAT are inhibited by the pan KCNQ channel blocker XE991 at 30 μM or the pan K~V~ channel blocker 4-aminopyridine (2 mmol/L; Fésüs et al., [@B12]; Schleifenbaum et al., [@B36]; Lee Y.-C. et al., [@B23]; Zavaritskaya et al., [@B55]). XE991 is a widely used pan K~V~7 channel blocker, which inhibits K~V~7.1 homomeric or K~V~7.1/KCNE channels (IC~50~ of \~0.8 μM and 11.1 μM, respectively; Wang et al., [@B47]), KCNQ2/3 channels (EC~50~ \~1 μM; Wang et al., [@B48]), KCNQ4 (EC~50~ \~5.5 μM; Søgaard et al., [@B39]), and KCNQ5 (EC~50~ \~65 μM; Schroeder et al., [@B37]). Noteworthy, XE991 can also inhibit other K~V~ channels, such as ERG (K~V~11; EC~50~ \~110 μM) (Elmedyb et al., [@B9]) and K~V~1.2/1.5, K~V~2.1/K~V~9.3 channels (\~30% inhibition at 10 μM) in heterologous expression systems (Zhong et al., [@B57]).

However, it is unknown whether XE991 is indeed specific for vascular K~V~ channels *in situ*, and does not inhibit native BK~Ca~ channels. This is particularly relevant since BK~Ca~ channels have been proposed to play a role in PVAT control of arterial tone in other studies (Lynch et al., [@B25]; Weston et al., [@B50]), although studies using BK~Ca~ deficient mice gave opposing results (Fésüs et al., [@B12]). A recent study showed that K~V~ channels in VSMCs of mouse mesenteric arteries are very sensitive to XE991 (EC~50~\~60 nM), suggesting that these channels may contribute to PVAT control of arterial tone (Schleifenbaum et al., [@B36], [@B35]). A very recent study suggested that diphenyl phosphine oxide-1 (DPO-1) sensitive K~V~1.5 channels could contribute to the K~V~ current in VSMC (Fancher et al., [@B11]).

Therefore, we tested whether K~V~1.5 channels are involved in the control of arterial tone and its regulation by PVAT or not. Our study is also aimed at extending our current knowledge on the *in situ* vascular pharmacology of DPO-1 and XE991 regarding K~V~1.5 and BK~Ca~ channels, in helping to identify the nature of K^+^ channels that could contribute to PVAT-mediated relaxation.

Methods {#s2}
=======

Mouse model
-----------

We used *Kcna5*^−/−^ mice as previously described (Pannasch et al., [@B30]). The mouse model was evaluated by RT-qPCR (Figure [S1](#SM1){ref-type="supplementary-material"}). Either litter- or age-matched (10--14 weeks old) male wild-type (129S6 background, previously known as 129SvEv-Ta) mice were used as controls. 250--300 g male Sprague Dawley rats were obtained from Charles River, Germany, Berlin. All experimental procedures were performed in accordance with the German legislation on protection of animals. Animal care followed American Physiological Society guidelines, and local authorities (Landesamt für Gesundheit und Soziales Berlin, *LAGeSo*) approved all protocols. Mice were housed in individually ventilated cages under standardized conditions with an artificial 12-h dark--light cycle with free access to water and food.

Wire myography
--------------

First order mesenteric arteries were removed immediately after killing the mice or rats under inhalation anesthesia with isoflurane by cervical dislocation, quickly transferred to cold (4°C), oxygenated (95% O~2~/5% CO~2~) physiological salt solution (PSS) containing (in mmol/L) 119 NaCl, 4.7 KCl, 1.2 KH~2~PO~4~, 25 NaHCO~3~, 1.2 MgSO~4~, 11.1 glucose, 1.6 CaCl~2~), and dissected into 2 mm rings whereby perivascular fat and connective tissue were either intact \[(+) PVAT or removed (−) PVAT\] without damaging the adventitia. Each ring was positioned on two stainless steel wires (diameter 0.0394 mm) in a 5-ml organ bath of a Mulvany Small Vessel Myograph (DMT 610 M; Danish Myo Technology, Denmark). The organ bath was filled with PSS. The bath solution was continuously oxygenated with a gas mixture of 95% O~2~ and 5% CO~2~, and kept at 37°C (pH 7.4) (Verlohren et al., [@B45]; Fésüs et al., [@B12]). The mesenteric rings were placed under a tension equivalent to that generated at 0.9 times the diameter of the vessel at 100 mm Hg by stepwise distending the vessel using LabChart DMT Normalization module. This normalization procedure was performed to obtain the passive diameter of the vessel at 100 mm Hg (Fésüs et al., [@B12]). The software Chart5 (AD Instruments Ltd. Spechbach, Germany) was used for data acquisition and display. After 60 min equilibration arteries were pre-contracted either with isotonic external 60 mmol/L KCl until a stable resting tension was acquired. The composition of 60 mM KCl (in mmol/L) was 63.7 NaCl, 60 KCl, 1.2 KH~2~PO~4~, 25 NaHCO~3~, 1.2 Mg~2~SO~4~, 11.1 glucose, and 1.6 CaCl~2~. Drugs were added to the bath solution if not indicated otherwise. Tension is expressed as a percentage of the steady-state tension (100%) obtained with isotonic external 60 mM KCl.

Isolation of arterial VSMCs
---------------------------

VSMCs from mesenteric arteries were isolated as described (Gollasch et al., [@B16]; Plüger et al., [@B33]). Briefly, the arteries were isolated and quickly transferred to cold (4°C) oxygenated (95% O~2~--5% CO~2~) PSS. The arteries were cleaned, cut into pieces, and placed into a Ca^2+^-free Hank\'s solution (in mmol/L): 55 NaCl, 80 sodium glutamate, 5.6 KCl, 2 MgCl~2~, 1 mg/ml bovine serum albumin (BSA, Sigma, Taufkirchen), 10 glucose, and 10 HEPES (pH 7.4 with NaOH) containing 0.5 mg/ml papain (Sigma) and 1.0 mg/ml DTT for 50 min at 37°C. The segments then were placed in Hank\'s solution containing 1 mg/ml collagenase (Sigma, type F and H, ratio 30 and 70%, respectively) and 0.1 mmol/L CaCl~2~ for 10 min at 37°C. Following several washes in Ca^2+^-free Hank\'s solution (containing 1 mg/ml BSA), single cells were dispersed from artery segments by gentle triturating. Cells were then stored in the same solution at 4°C.

Electrophysiology
-----------------

Voltage dependent potassium (K~V~) currents and BK~Ca~ currents were measured in the conventional whole-cell configuration of the patch-clamp technique at room temperature as previously described (Gollasch et al., [@B15]; Essin et al., [@B10]; Schleifenbaum et al., [@B35]). Patch pipettes (resistance 3--5 MΩ) for recording K~V~ currents were filled with a solution containing (in mmol/L): 130 KCl, 1 MgCl~2~, 3 Na~2~ATP, 0.1 Na~3~GTP, 10 HEPES, and 5 EGTA (pH 7.2; Yeung and Greenwood, [@B53]). Patch pipettes for recording BK~Ca~ currents contained (in mmol/L): 130 KCl, 1 MgCl~2~, 3 Na~2~ATP, 0.1 Na~3~GTP, 10 HEPES, 5 EGTA, and 4.3 CaCl~2~ (estimated \[Ca^2+^\] free, 10^−6^ mol/L; pH 7.2). The external bath solution contained (in mmol/L): 126 NaCl, 5 KCl, 1 MgCl~2~, 0.1 CaCl~2~, 11 glucose and 10 HEPES (pH 7.2; Yeung and Greenwood, [@B53]). Holding potential was −60 mV. Whole cell currents were recorded using an Axopatch 200B amplifier (Axon Instruments/Molecular Devices, Sunnyvale, CA, USA) or an EPC 7 amplifier (List, Darmstadt, Germany) and digitized at 5 kHz, using a Digidata 1440A digitizer (Axon CNS, Molecular Devices), and pClamp software versions 10.1 and 10.2 (Schleifenbaum et al., [@B35]).

RT-qPCR
-------

Total RNA was isolated from snap-frozen heart and aortae tissues with or without K~V~1.5 by using the RNeasy RNA isolation kit (Qiagen, Hamburg, Germany) according to the manufacturer\'s instruction. Isolated RNA concentration was measured and RNA quality was tested by NanoDrop-1000 spectrophotometer (PeqLab, Erlangen, Germany). For the synthesis of cDNA, equivalent amounts of RNA (2 μg) were used and processed by a high capacity cDNA reverse transcription kit (Life Technologies GmbH, Darmstadt, Germany). Quantitative analysis of target mRNA expression was performed with real-time PCR using the relative standard curve method (Markó et al., [@B27]). TaqMan or SYBR green analysis was conducted according to the manufacturer\'s instructions, using an Applied Biosystems 7500 Sequence Detector (Life Technologies Corporation, Carlsbad, CA, USA). The expression level of the target genes was normalized by the expression of 18S. Primers for were synthesized by Biotez (Berlin, Germany) and the sequences are as follows: K~V~1.5 Forward sequence: 5′-GCTACTTCGATCCCTTGAGAAAT-3′; Reverse sequence: AGTAGTACAAAATGCCATCGAAGCT, 18S Forward sequence: 5′-ACATCCAAGGAAGGCAGCAG-3′; Reverse sequence 5′-TTTTCGTCACTACCTCCCCG-3′.

Materials
---------

All salts and other chemicals were obtained from Sigma-Aldrich (Germany) or Merck (Germany). All drugs were freshly dissolved on the day of each experiment according to the material sheet. The following concentrations of drugs were used: phenylephrine (Sigma-Aldrich) ranged from 0.01 to 100 μmol/L, 5-HT from 0.01 to 10 μM, DPO-1 (Tocris) 1 and 10 μmol/L, 100 nmol/L iberiotoxin (Sigma Aldrich). XE991 (Tocris) was applied at concentrations between 0.3 and 30 μM.

Statistics
----------

Data represent mean ± SEM. EC~50~ values were calculated using a Hill equation: T = (B~0~ − Be)/(1 + (\[D\]/EC~50~)^n^) + Be, where T is the tension in response to the drug (D); Be is the maximum response induced by the drug; B~0~ is a constant; EC~50~ is the concentration of the drug that elicits a half-maximal response (Bychkov et al., [@B3]). Curve fittings were done by Prism 6 software using non-linear regression. Statistical significance was determined by two-way ANOVA or repeated-measures two-way ANOVA, followed by Bonferroni *post hoc* test, and using Prism 6 software. In case of unbalanced data, this software uses analysis of "unweighted means" to compare groups. Extra sum-of-squares *F*-test was performed for comparison of concentration-response curves and their 95% confidence intervals (CI). *P*-values \< 0.05 were considered statistically significant. n represents the number of independent arteries tested or the number of cells measured. All rings were obtained from at least 3 different animals.

Results {#s3}
=======

Regulation of arterial tone by DPO-1 sensitive K~V~1.5 channels
---------------------------------------------------------------

First, we examined the role of K~V~1.5 channels in the regulation of arterial tone by alpha1 adrenoceptor (alpha~1~-AR) stimulation. In this set of experiments, we used the K~V~1.5 channel blocker DPO-1 at concentrations assumed to be specific and potent for K~V~1.5 channel inhibition (Stump et al., [@B41]; Lagrutta et al., [@B21]; Regan et al., [@B34]). In the presence of 1 μM DPO-1, mesenteric artery rings without PVAT \[(−) PVAT\] displayed similar contractions in response to phenylephrine (PE) compared to non-treated (−) PVAT control rings (Figures [1A,B](#F1){ref-type="fig"}). The 95% CI for EC~50~ of control and DPO-1 treated rings were 1.21--1.79 μM and 0.78--1.40 μM, respectively. The anti-contractile effects of PVAT were also unchanged by 1 μM DPO-1: the 95% CI for EC~50~ of control (+) PVAT and 1 μM DPO-1 (+) PVAT treated rings were 3.99--8.14 μM and 4.99--10.05 μM, respectively. To further confirm the results obtained with the K~V~1.5 channel inhibitor, we performed similar experiments using mesenteric artery rings from *Kcna5*^−/−^ mice. PE induced vasocontractions in (−) PVAT *Kcna5*^−/−^ rings were not different from those observed in (−) PVAT *Kcna5*^+/+^ rings (Figures [1C,D](#F1){ref-type="fig"}). Similarly, we observed PE induced vasocontractions in (+) PVAT *Kcna5*^−/−^ rings, which were not different from those observed in (+) PVAT *Kcna5*^+/+^ rings (Figures [1C,D](#F1){ref-type="fig"}). The 95% CI for EC~50~ of (−) PVAT and (+) PVAT arteries isolated from *Kcna5*^−/−^ mice were 0.81--1.30 μM and 4.94--7.79 μM, respectively. Data are summarized in Table [1](#T1){ref-type="table"}. Experiments on rat mesenteric arteries showed similar results: Cumulative dose-response curves in response to serotonin (5-HT) were similar in vessel rings in the absence or presence of DPO-1 (Figure [1E](#F1){ref-type="fig"}). Together, the results suggest that K~V~1.5 channels do not play a functionally relevant role in the control of arterial tone by PVAT, α1-AR and 5-HT agonists, in both mouse and rat mesenteric arteries.

![**Effects of pharmacological blockade and genetic deletion of K~**V**~1.5 channels on regulation of arterial tone by perivascular adipose tissue (PVAT), phenylephrine (PE), and serotonin (5-HT). (A)** Original traces showing the effects of 1 μM DPO-1 on PE-induced contractions in (−) PVAT and (+) PVAT mesenteric artery rings compared with control rings without DPO-1. **(B)** Concentration-response relationships for PE-induced contractions in *Kcna5*^+/+^ (+) PVAT (*n* = 8) or (−) PVAT (*n* = 9) mesenteric arteries in the absence of DPO-1 or in *Kcna5*^+/+^ (+) PVAT (*n* = 8) and (−) PVAT (*n* = 9) arteries after 30 min of pre-incubation with 1 μM DPO-1. ^\*^*p* \< 0.05, for (−) PVAT vs. (+) PVAT or (−) PVAT + DPO-1 vs. (+) PVAT + DPO-1; repeated-measures two-way ANOVA, followed by Bonferroni *post hoc* test. **(C)** Original traces showing the effects of genetic deletion of *Kcna5* on PE-induced contractions in (−) PVAT and (+) PVAT mesenteric artery rings. **(D)** PE-induced contractions of (+) PVAT and (−) PVAT artery rings isolated from *Kcna5*^+/+^ \[(+) PVAT, *n* = 8; (−) PVAT, *n* = 9\] and *Kcna5*^−/−^ \[(+) PVAT, *n* = 12; (−) PVAT, *n* = 12\] mice. ^\*^*p* \< 0.05, for (−) PVAT *Kcna5*^+/+^ vs. (+) PVAT *Kcna5*^+/+^ or (−) PVAT *Kcna5*^−/−^ vs. (+) PVAT *Kcna5*^−/−^. **(E)** Cumulative concentration-response relationships to 5-HT in (+) PVAT (*n* = 7) and (−) PVAT rat mesenteric arteries (*n* = 6) and the effects of 1 μM DPO-1 on (+) PVAT (*n* = 6) and (−) PVAT rat mesenteric arteries (*n* = 8). ^\*^*p* \< 0.05, for (−) PVAT vs. (+) PVAT or (−) PVAT + DPO-1 vs. (+) PVAT + DPO-1; repeated-measures two-way ANOVA, followed by Bonferroni *post hoc* test.](fphys-07-00335-g0001){#F1}

###### 

**EC~**50**~ and its confidence intervals**.

  **Condition**              **Mouse background**   **Without PVAT**   **With PVAT**                             
  -------------------------- ---------------------- ------------------ --------------- ---- ------ ------------- ----
  *Kcna5*^+/+^               129SVE-M               1.48               1.21--1.79      9    5.72   3.99--8.14    8
  *Kcna5*^−/−^               129SVE-M               1.02               0.81--1.30      10   6.20   4.94--7.79    12
  *Kcna5*^+/+^ +1 μM DPO-1   129SVE-M               1.04               0.78--1.40      11   7.24   4.99--10.05   11
  Control                    C57BL/6                0.70               0.57--0.87      17   4.94   4.18--5.84    21
  0.3 μM XE991               C57BL/6                0.48               0.30--0.75      5    2.43   1.92--3.09    13
  30 μM XE991                C57BL/6                0.38               0.24--0.65      5    1.64   1.32--2.02    12

*Data calculated from concentration-response curves to phenylephrine after normalization to maximum response from within each curve. For comparison of data and groups, see text and figures*.

DPO-1 sensitive K~V~ channels distinct from K~V~1.5 may regulate arterial tone
------------------------------------------------------------------------------

Next, we studied putative non-K~V~1.5 channel dependent effects by using higher concentrations of DPO-1. Figure [2A](#F2){ref-type="fig"} shows that 1 μM DPO-1 had no effects on basal tone of *Kcna5*^+/+^ mesenteric artery rings with and without PVAT. Surprisingly, application of 10 μM DPO-1 resulted in a stable contraction of *Kcna5*^+/+^ mesenteric arteries without but not with PVAT (Figure [2B](#F2){ref-type="fig"}). This effect remained stable over 30 min and was observed also on rings isolated from *Kcna5*^−/−^ mice (Figure [2C](#F2){ref-type="fig"}). Thus, unexpectedly, inhibition of DPO-1 sensitive K~V~ channels distinct from K~V~1.5 channels or other pathways could contribute to vascular tone in this preparation.

![**Effects of 1 μM and 10 μM DPO-1 on basal arterial tone of mesenteric artery rings isolated from ***Kcna5***^**+/+**^ and ***Kcna5***^**−/−**^ mice**. Original traces showing contraction of mesenteric (−) and (+) PVAT rings induced by 60 mmol/L KCl and by 1 μM (**A**) and 10 μM DPO-1 (**B**). (**C**) Vessel tension induced by 10 μM DPO-1. Tension is expressed as a percentage of KCl contractions. *Kcna5*^+/+^ (−) PVAT, *n* = 9; (+) PVAT, *n* = 13. *Kcna5*^−/−^ (−) PVAT, *n* = 7; (+) PVAT, *n* = 9. ^\*^*p* \< 0.05, two-way ANOVA followed by Bonferroni *post hoc* test.](fphys-07-00335-g0002){#F2}

Effects of XE991 on K~V~ currents, BK~Ca~ currents and the anti-contractile effects of PVAT
-------------------------------------------------------------------------------------------

K~V~ currents were recorded in mesenteric artery VSMCs freshly isolated from *Kcna5*^+/+^ and *Kcna5*^−/−^ mice. We did not observe any difference between K~V~ current densities in *Kcna5*^+/+^ and *Kcna5*^−/−^ VSMCs. Moreover, K~V~ current inhibition by 30 μM XE991 was not different between *Kcna5*^+/+^ and *Kcna5*^−/−^ VSMCs (Figures [3A,B](#F3){ref-type="fig"}). 30 μM XE991 did not affect basal tone of mesenteric arteries prepared with or without PVAT (Figure [S2](#SM1){ref-type="supplementary-material"}).

![**Voltage dependent (K~**V**~) K^**+**^ currents and BK~**Ca**~ currents in freshly-isolated mesenteric artery vascular smooth muscle cells (VSMCs) from ***Kcna5***^**−/−**^ and ***Kcna5***^**+/+**^ mice**. K~V~ currents before (−XE991) and after (+XE991) application of 30 μM XE991. Current densities of peak K~V~ currents **(A)** (*n* = 6 *Kcna5*^−/−^ cells, *n* = 10 *Kcna5*^+/+^ cells, before and after application of XE991, respectively); original recordings **(B)**. **(C)** Relative inhibition of peak BK~Ca~ current by iberiotoxion (IbTx) at 100 nM (*n* = 5) and XE991 at 30 μM (*n* = 9) in *Kcna5*^+/+^ VSMCs, original recordings are represented in **(D)**.](fphys-07-00335-g0003){#F3}

In order to better understand the effects of XE991, we tested its actions on BK~Ca~ currents, potential mediators of the PVAT effect. VSMC *Kcna5*^+/+^ BK~Ca~ currents were recorded in the absence and presence of 30 μM XE991. 100 nM iberiotoxin (a potent and highly selective BK~Ca~ channel inhibitor) was used as positive control. While 30 μM XE991 did not affect the BK~Ca~ current, iberiotoxin almost completely inhibited the BK~Ca~ current. These results are consistent with plasma membrane VSMC BK~Ca~ channel activity resistant to XE991 *in situ*, at concentrations up to 30 μM of XE991 (Figures [3C,D](#F3){ref-type="fig"}).

Additionally, we tested the effects of 30 μM and 0.3 μM XE991 on the paracrine effects of PVAT on arterial tone. We found that XE991 even at the low concentration abolished the anti-contractile effects of PVAT. Interestingly, application of 0.3 and 30 μM XE991 resulted in a similar reduction of the anti-contractile effects of PVAT (Figures [4A,B](#F4){ref-type="fig"}). The EC~50~ 95% CI values were 1.92--3.09 and 1.32--2.02 μM for (+) PVAT rings preincubated with 0.3 μM XE991 and 30 μM XE991, respectively; and 4.18--5.84 μM for (+) PVAT rings in the absence of XE991. (−) PVAT rings showed no difference, regardless of the absence or presence of 0.3 μM or 30 μM XE991. Data are presented in Table [1](#T1){ref-type="table"}. Together, our data demonstrate that XE991 is a potent inhibitor of PVAT control of arterial tone at low concentrations similar to its potency of inhibiting K~V~ currents in VSMCs (Schleifenbaum et al., [@B35]). BK~Ca~ channels are however exempt from this inhibitory effect of XE991 (up to 30 μM).

![**Effects of XE991 on regulation of arterial tone by perivascular adipose tissue**. Cumulative concentration-response curves to PE in the presence of 30 μM XE991 **(A)** and 0.3 μM XE991 **(B)**, expressed as a percentage of KCl contractions. (−) PVAT, *n* = 17; (+) PVAT, *n* = 21. (+) PVAT (+) 30 μM XE991, *n* = 12; (+) PVAT + 0.3 μM XE991, *n* = 13; (−) PVAT (+) 30 μM XE991, *n* = 5; (−) PVAT + 0.3 μM XE991, *n* = 5. ^\*^*p* \< 0.05, repeated-measures two-way ANOVA, followed by Bonferroni *post hoc* test ^\*^ in **(A)**, (+) PVAT vs. (+) PVAT + 30 μM XE991. ^\*^In **(B)**, (+) PVAT vs. (+) PVAT + 0.3 μM XE991. Experiments were performed on mouse mesenteric arteries.](fphys-07-00335-g0004){#F4}

Discussion {#s4}
==========

Perivascular adipose tissue plays a potent anti-contractile role in the control of arterial tone along arterial segments of different vascular beds and species. The main findings of this study are threefold. First, XE991 inhibits the PVAT effect at nanomolar concentrations in mesenteric arteries of mice. Interestingly, similar concentrations were found in earlier studies to inhibit VSMC K~V~ currents (50% inhibition at 60 nM XE991) (Schleifenbaum et al., [@B35]). Second, *Kcna5*^−/−^ mice exhibited normal VSMC K~V~ currents and arterial contractions in the absence and presence of PVAT, whose effects were insensitive to DPO-1. Third, the KCNQ channel blocker XE991 does not affect plasma membrane VSMC BK~Ca~ channels at concentrations, which inhibit the anti-contractile effects of PVAT. Together, the results of our current study implicate KCNQ-type K~V~ channels in the XE991-mediated inhibition of the PVAT effects. Simultaneously, we exclude BK~Ca~ as well as K~V~1.5 channels as potential downstream candidates in this process.

K~V~1.5 in regulation of arterial tone
--------------------------------------

In recent studies, K~V~1.5 channels have been shown to determine microvascular tone and the arteriolar response to vasoconstrictors in rat cerebral arteries (Chen et al., [@B4]; Fancher et al., [@B11]). Furthermore, K~V~1.5 channels in the heart are essential in coupling myocardial blood flow to cardiac metabolism (Ohanyan et al., [@B29]). Moreover, hypertension is associated with altered expression of vascular K~V~1.5 channels (Wang et al., [@B49]; Platoshyn et al., [@B32]; Cox and Rusch, [@B7]; Cox et al., [@B6]; Cidad et al., [@B5]). Therefore, K~V~1.5 channels may represent interesting putative targets of PVAT and that raised the question of their potential involvement in the regulation of arterial tone by phenylephrine in mouse mesenteric arteries. Our results suggest that K~V~1.5 channels are however not involved. In effect, the anti-contractile effects of PVAT were not different between *Kcna5*^−/−^ and *Kcna5*^+/+^ arteries. Additionally, the K~V~1.5 channel inhibitor DPO-1 at 1 μM displayed no effect on vasocontractions in the absence and presence of PVAT. Notably, the mechanism of DPO-1 action ("open channel" blocker) might be a potential confounding factor, since K~V~1.5 channels are activated at V~0.5~ of −14 mV (Grissmer et al., [@B18]). However, the genetic approach had the advantage to study vascular effects in the absence of K~V~1.5 channels avoiding possible confounders related to membrane potential-dependent drug mechanisms. Furthermore, we did not observe any significant differences in the K~V~ current density and inhibition by XE991 in *Kcna5*^−/−^ and *Kcna5*^+/+^ VSMCs. Therefore, we conclude that K~V~1.5 channels have no apparent role in PVAT-dependent relaxation and are not the XE991 sensitive channels that contribute to this process. This conclusion is in line with our previous results obtained on cloned and heterologously expressed K~V~1.5 alpha subunits in HEK293 cells (Schleifenbaum et al., [@B35]). In these experiments, 100 nM XE991 failed to block K~V~1.5 currents. We also observed similar responses of arterial rings without PVAT to PE and 5-HT, regardless of genetic deletion of K~V~1.5 alpha subunits or pharmacological blockade of K~V~1.5 channels by DPO-1. To our knowledge, this is the first study to firmly establish that K~V~1.5 channels are not involved in the regulation of arterial tone of systemic visceral arteries of mice and rats, at least in mesenteric arteries. Our conclusions substantiate the work of other groups, namely that patients with genetic mutations of *KCNA5* exhibit pulmonary arterial hypertension and arterial fibrillation but not systemic hypertension (Yang et al., [@B52]; Wipff et al., [@B51]; Machado et al., [@B26]). Together, our data questions the contribution of K~V~1.5 channels in a number of small resistance arteries to peripheral arterial resistance. The findings are however not generalizable to all vascular beds as K~V~1.5 channels were demonstrated to play important vasoregulatory functions in cerebral arteries and in *Gracilis* skeletal muscle arteries (Chen et al., [@B4]; Fancher et al., [@B11]).

DPO-1 sensitive K^+^ channels and pathways distinct from K~V~1.5 involved in regulation of arterial tone
--------------------------------------------------------------------------------------------------------

DPO-1 was described as a specific K~V~1.5 inhibitor at micromolar concentrations (Stump et al., [@B41]; Lagrutta et al., [@B21]; Regan et al., [@B34]). It exerts its inhibitory effects through binding with several key residues in the S5- pore loop-S6 domains, thus resulting in blockade of the open state of the K~V~1.5 channel (Karczewski et al., [@B19]; Du et al., [@B8]). Other studies have suggested a DPO-1 preference for vascular K~V~1.5 channels, though with limited selectivity (Fancher et al., [@B11]). In this study, DPO-1 (1--10 μM) inhibited the outward K^+^ current in arterial smooth muscle cells from wild-type (*Kcna5*^+/+^) mice and mice lacking the *Kcna5* gene; however, the inhibitory effect was much greater in cells from *Kcna5*^+/+^ mice (Fancher et al., [@B11]). Subsequently, our data in Figure [2](#F2){ref-type="fig"} suggests that 10 μM DPO-1 induces contractions by inhibiting channels distinct from K~V~1.5 channels. Those channels appear to be important for the regulation of resting arterial tone. Interestingly, DPO-1 is able to block K~V~1.3 channel currents at EC~50~ of 3.1 μM in human T cells (Zhao et al., [@B56]). *Kcna3* mRNA expression is also observed in mouse mesenteric arteries (Fountain et al., [@B13]; Cidad et al., [@B5]). Although the ability of K~V~1.5 and K~V~1.3 to form heteromers (Kv1.5/Kv1.3) (Villalonga et al., [@B46]) impede the study of their specific roles in native tissues *in vivo*, it is intriguing to speculate that K~V~1.3 channels could represent a putative target of PVAT regulation of arterial tone. Future studies are necessary to clarify their role.

Effects of XE991 on K~V~ channels, BK~Ca~ channels and paracrine PVAT effects
-----------------------------------------------------------------------------

In the mouse mesenteric arteries, *Kcnq1, Kcnq4*, and *Kcnq5* expression was demonstrated at the mRNA level (Yeung et al., [@B54]), whereas mRNA expression of *Kcnq2, Kcnq3* was not detectable or only at borderline low levels (Yeung et al., [@B54]; Schleifenbaum et al., [@B35]). We previously suggested that KCNQ type K~V~ channels are key players in the paracrine role for periadventitial adipose tissue in the regulation of arterial tone (Schleifenbaum et al., [@B36]; Zavaritskaya et al., [@B55]); based on mRNA expression levels (see above), KCNQ1, KCNQ4, and/or KCNQ5 channels are likely candidates. This suggestion is also based on the ability of 30 μM XE991 (pan KCNQ blocker) and 2 mmol/L 4-aminopyridine (pan K~V~ blocker) to block the anti-contractile effects of PVAT. Interestingly, KCNQ channel openers normalized reduced anti-contractile effects of PVAT in a rat model of hypertension (Zavaritskaya et al., [@B55]), which suggests therapeutic perspectives of KCNQ targeting in cardiovascular disease. It is thus imperative to better understand the actions of these compounds on the vasculature. In order to obtain more information about the potency of XE991 inhibition on PVAT-mediated anti-contractility, we performed experiments with a 100x lower concentration of XE991. The data show that this considerably reduced concentration still exerted an inhibitory impact on PVAT regulation of arterial tone (Figures [4A,B](#F4){ref-type="fig"}), while basal tone was unaffected in rings (+) or (−) PVAT (Figure [S2](#SM1){ref-type="supplementary-material"}). The incomplete inhibition observed, however suggests the possible involvement of additional K^+^ channels in this process. Furthermore, our data demonstrates that VSMC plasma membrane BK~Ca~ channels are not involved in the effects of XE991 on PVAT regulation, since XE991 does not inhibit BK~Ca~ currents (this study). This is in line with our previous findings indicating that the paracrine effects of PVAT on arterial tone are normal in the presence of BK~Ca~ channel blockers or in arteries that lack BK~Ca~ beta1 channel subunits (Fésüs et al., [@B12]; Zavaritskaya et al., [@B55]).

Previous studies examined the ability of XE991 to inhibit heterologously expressed K~V~1.5 alpha subunits. We found that 100 nM and 30 μM XE991 was unable to block monotetrameric K~V~1.5 channels heterologously expressed in HEK293 or CHO cells (Zavaritskaya et al., [@B55]; Schleifenbaum et al., [@B35]). Interestingly, Zhong et al. found a small (\~20% at (+) 5 mV) inhibiting effect for 10 μM XE991 on heterologously expressed heterotetrameric K~V~1.2/K~V~1.5 and K~V~2.1/K~V~9.3 channel subunits (Zhong et al., [@B57]). The block of K~V~1.2/K~V~1.5 channels was voltage dependent, and evident only at voltages positive to -15 mV. Our present study contributes to the debate about the importance of accessory subunits for determining the pharmacological properties of vascular K^+^ channels *in vivo*. Since regulatory K~V~beta1.3 subunits can decrease the sensitivity of K~V~1.5 channels to pharmacological inhibitors such as DPO-1 (Gonzalez et al., [@B17]; Arias et al., [@B1]; Du et al., [@B8]), one could argue that DPO-1 is not a reliable tool to study K~V~1.5 channels in native tissues. However, we believe that our pharmacological approach in combination with the *Kcna5*^−/−^ mouse model firmly demonstrates that the XE991 sensitive regulation of arterial tone by PVAT regulation does not involve native vascular K~V~1.5 channels.

Conclusion {#s5}
==========

In conclusion, our results demonstrate that K~V~1.5 channels are not involved in the control of mesenteric arterial tone and its regulation by PVAT in mouse and rat mesenteric arteries. The nature of the 10 μM DPO-1 sensitive component is unclear, but is most likely related to non-specificity of this drug, for example in targeting vascular K~V~1.3 and/or KCNQ channels *in situ*. Importantly, the inhibitory effects of XE991 on PVAT vasorelaxation are rather related to inhibition of KCNQ-type K~V~ channels than BK~Ca~ channels. These data unequivocally substantiate the hypothesis of different targets of perivascular relaxing factor(s), which employ distinct mechanisms to mediate an anti-contractile effect. Further studies should focus on the enhancement of these relaxing factors, as these will be beneficial for patients with cardiovascular diseases.
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